Stallergenes Phase III data for sublingual allergy tablet support U.S. and EU submissions

Stallergenes Greer plc (Euronext:STAGR) said its once-daily house dust mite sublingual tablet (STAGR320) met the primary endpoint in a Phase III trial to treat house dust mite-induced allergic rhinitis.

The company said the data support a path for submitting regulatory applications in the U.S. and Europe. The sublingual allergy immunotherapy tablet is approved as Actair to treat house dust mite-induced allergic rhinitis in Japan, Australia, New Zealand and South Korea...